Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FAM49B/CYRIB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FAM49B/CYRIB Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Theoretical MW optimized for PPI assays. |
View FAM49B Products |
| Gene Delivery | FAM49B/CYRIB Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional migration assays. |
View FAM49B Products |
| Benchmark Ab | Anti-FAM49B/CYRIB Recombinant Antibody High-affinity sequence-verified positive control for Western Blot, IHC, and IP. |
View FAM49B Products |
| Validator | FAM49B/CYRIB siRNA Set Target-specific knockdown pool for validating phenotypic rescue and pathway specificity. |
View FAM49B Products |
| Related Target A | RAC1 Direct binding partner. CYRIB acts as a negative regulator of RAC1 to suppress lamellipodia formation. |
View RAC1 Products |
| Related Target B | CYFIP1 Functional competitor. CYRIB competes with CYFIP1 for binding to active RAC1 to regulate WAVE dynamics. |
View CYFIP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening (CYRIB-RAC1) | Tags optimized (GST/His) for GST pull-down and TR-FRET assays; high purity (>95%) ensures low background. |
| Cellular migration & invasion phenotyping | Lentivirus premade particles for robust, stable expression in tumor and immune cell lines without transient transfection toxicity. |
| Lack of verified positive controls | Sequence-verified recombinant benchmark antibodies available for western blot and immunoprecipitation. |
| Target specificity validation | Sequence-designed siRNA pool included to confirm target-specific phenotypic reversal. |
Live FAM49B/CYRIB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FAM49B/CYRIB therapeutics is intensifying, with major players shifting focus from traditional targets to RAC1-pathway modulators. As first-generation cytoskeletal regulators reach the clinic, the next wave of R&D is targeting the CYRIB-RAC1 interface to control tumor metastasis and T-cell infiltration. Because CYRIB acts as a native "brake" on RAC1-mediated actin polymerization, therapeutic approaches focus on either stabilizing this interaction in hyperactive RAC1 cancers or modulating it in immunology contexts.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Stabilizers) | Academic Consortia, Biotech Startups | Metastatic Solid Tumors, Glioma | High-purity recombinant proteins for TR-FRET and SPR binding assays. |
| Gene Therapy / mRNA | Oncology Therapeutics Specialists | Invasive Carcinomas | Lentivirus for stable overexpression to assess inhibition of lamellipodia. |
| siRNA / Antisense | RNAi Therapeutics Developers | Immunotherapy Combinations | Sequence-verified target siRNA for knock-down reference and specificity controls. |